Please assess the completion status of the following clinical trial:

Trial Title: CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All the criteria below have to be completed:~1. Systemic lupus erythematosus (SLE) according to the American College of Rheumatology (ACR) classification criteria and/or SLICC: according to the thematic protocol (Petri M, et al., Arthritis Rheum, 2012);~2. Age ≥18 years;~3. Lupus Glomerulonephritis Class III, IV or V according to the International Society of Nephrology (ISN)/Renal Pathology Society (RPS) Classification confirmed on renal biopsy (according to the routine protocol of our outpatient clinic) performed up to 3 months to 1 year prior to selection;~4. Menopause or use contraception method;~5. Informed consent.~Exclusion Criteria:~1. Creatinine clearance \< 40 ml/min calculated (Cockcroft \& Gault);~2. Intolerance to medication;~3. Absolute neutrophil count \< 1,000/mm3;~4. Pregnancy or breastfeeding;~5. Infection requiring hospitalization;~6. Patients who used Cyclophosphamide in the last 6 months or biological in the last year;~7. Thrombotic renal microangiopathy;~8. Chronic terminal renal disease and/or class VI biopsy;~9. Non-adhesion profile;~10. Need to use another therapeutic scheme;~11. GC dose in the last 3 months not greater than 20mg/day.~11.Central nervous system (CNS) disorders or hemolytic anemia and severe thrombocytopenia (\< 50,000 platelets/mm3).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eurolupus: Cyclophosphamide + Methylprednisolone + oral GC (Type: ACTIVE_COMPARATOR): The EUROLUPUS group will receive Cyclophosphamide (6 doses of 500 mg / fortnightly) + 3 doses of Methylprednisolone (750 mg) initial + oral glucocorticoid (GC) (prednisone) ≤ 30 mg/day with a gradual reduction of 5 mg/month (EUROLUPUS). From the 3rd month, the group will receive oral mycophenolate mofetil (MMF) (2-3 g) until 6 months with gradual reduction of GC from 5 mg/month until the minimum dose of 5 mg/month.
- Cyclones Group: Cyclophosphamide+Methylprednisolone no oral GC (Type: EXPERIMENTAL): CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg / fortnightly) + Methylprednisolone \[500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)\] without oral glucocorticoid (GC). From the third month, the group will receive only oral MMF (2-3 g) until the 6th month. Patients using GC ≤ 20 mg/day may enter the protocol with immediate reduction to 15 mg/day with a reduction of 5mg/month until complete withdrawal.

Based on this trial design, predict the completion outcome and termination type (if applicable).